Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)

Next Previous
Trial Profile

An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; DS-1594 (Primary) ; Venetoclax (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Filgrastim; Folinic acid; Folinic acid; Mesna; Methotrexate; Posaconazole; Prednisone; Rituximab; Vincristine; Voriconazole
  • Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 23 May 2025 Status changed from completed to discontinued as supporting/funding source decided to de-prioritize and stop development of DS-1594
  • 09 Nov 2023 Status changed from active, no longer recruiting to completed.
  • 14 Mar 2023 Planned End Date changed from 30 Nov 2022 to 30 Nov 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top